Boston Scientific said it is unlikely to meet its third-quarter and full-year 2026 net-sales and adjusted-earnings guidance after an August 25 cybersecurity incident disrupted manufacturing, order fulfillment and shipments globally. The company had forecast full-year sales growth of 5.5% to 6.5% and adjusted earnings of $3.28 to $3.32 a share, while its third-quarter outlook called for sales growth of 3% to 5% and adjusted earnings of 80 cents to 82 cents a share. Logistics operations, sterilization facilities and most manufacturing sites have resumed, and the company said it has found no evidence of continuing unauthorized access, though recovery and its investigation remain incomplete. Boston Scientific expects to recapture some lost revenue but has not determined the total financial impact. The warning follows two earlier reductions to its annual outlook, including a late-July cut tied to weaker-than-expected Watchman heart-implant performance. Shares fell more than 4% to $45.73 on Tuesday, extending a decline of roughly 50% this year.